ClinicalTrials.gg
CompletedNCT03848416Updated Jun 24, 2020Results posted

A Study of Ixekizumab in Healthy Participants

A Phase 1 interventional study of Ixekizumab in Healthy, sponsored by Eli Lilly and Company. Completed at 1 site in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-06-24.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
99
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The purpose of this study is to compare three different formulations of ixekizumab. One formulation (Reference) has been approved by the Food and Drug Administration (FDA) and two formulations (Test 1 and Test 2) have not been approved. This study will compare how much of each of the three formulations get into the blood stream. Information about any side effects that may occur will also be collected.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.

Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male participant or female participant who agree to not become pregnant
  • Are male participant or female participants with chronic stable medical problems, that in the investigator's opinion will not place the subject at increased risk by participating in the study

Exclusion criteria

Exclusion Criteria:

  • Have a significant history of, or current, cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, or hematologic disorders that in the opinion of the investigator poses an unacceptable risk to the participant if participating in the study
  • Are allergic or hypersensitive to the study medicine
  • Had a vaccination with a within 12 months prior to the first check-in or intend to get a vaccine for tuberculosis within 12 months of completing treatment on this study
  • Have any type of hepatitis, (HIV) infection, or other serious infection
  • Show evidence of active or latent tuberculosis (TB)
  • Presence of significant neuropsychiatric disorder or a recent history of depression
  • Have had any active or recent infection within 4 weeks of Day 1 that, in the opinion of the investigator would pose an unacceptable risk to the participant, if participating in the study
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
99 participants (actual)

Study arms

  • Experimental
    Ixekizumab (Reference)

    Reference formulation ixekizumab 80 milligram (mg) administered as a subcutaneous (SC) injection in a prefilled syringe.

    Biological: Ixekizumab

  • Experimental
    Ixekizumab (Test 1)

    Test 1 formulation ixekizumab 80 mg administered as an SC injection in a prefilled syringe.

    Biological: Ixekizumab

  • Experimental
    Ixekizumab (Test 2)

    Test 2 formulation ixekizumab 80 mg administered as an SC injection in a prefilled syringe.

    Biological: Ixekizumab

Interventions

  • BiologicalIxekizumab

    Administered SC

    Also known as: LY2439821

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK): Maximum Concentration (Cmax) of Ixekizumab

    Pharmacokinetics (PK): Maximum Concentration (Cmax) of a single dose of Ixekizumab

    Time frame: Predose, Day 3, Day 5, Day 11, Day 15, Day 22, Day 29, Day 36, Day 43, Day 57, Day 71 and Day 85 Post Dose

  2. PK: Area Under the Plasma Concentration Versus Time Curve (AUC) From Time Zero to the Last Measured Concentration Value (AUC[0-tlast]) of Ixekizumab

    Area under the plasma concentration versus time curve from time zero to the last measured concentration value (AUC\[0-tlast\]). AUC 0-tlast is equal to AUC (0-85) days where the last time point was 85 Days ± 3 Days.

    Time frame: Predose, Day 3, Day 5, Day 11, Day 15, Day 22, Day 29, Day 36, Day 43, Day 57, Day 71 and Day 85 Post Dose

  3. PK: Area Under the Plasma Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of Ixekizumab.

    Area under the plasma concentration versus time curve from zero to infinity (AUC\[0-∞\]) of a single dose of Ixekizumab.

    Time frame: Predose, Day 3, Day 5, Day 11, Day 15, Day 22, Day 29, Day 36, Day 43, Day 57, Day 71 and Day 85 Post Dose

07

Results

Posted Jun 24, 2020

Participant flow

Participant flow — Overall Study
MilestoneIxekizumab (Reference)Ixekizumab (Test 1)Ixekizumab (Test 2)
Started333333
Received at least one dose of study drug333333
Completed323332
Not completed101
Withdrew: Withdrawal by subject100
Withdrew: Death001

Outcome measures

PrimaryPharmacokinetics (PK): Maximum Concentration (Cmax) of Ixekizumab

Pharmacokinetics (PK): Maximum Concentration (Cmax) of a single dose of Ixekizumab

Time frame:
Predose, Day 3, Day 5, Day 11, Day 15, Day 22, Day 29, Day 36, Day 43, Day 57, Day 71 and Day 85 Post Dose
Reported as:
Geometric mean · microgram/milliliter (ug/mL)
Pharmacokinetics (PK): Maximum Concentration (Cmax) of Ixekizumab
microgram/milliliter (ug/mL)Ixekizumab (Reference)Ixekizumab (Test 1)Ixekizumab (Test 2)
Pharmacokinetics (PK): Maximum Concentration (Cmax) of Ixekizumab6.31 ± 486.29 ± 336.50 ± 33
PrimaryPK: Area Under the Plasma Concentration Versus Time Curve (AUC) From Time Zero to the Last Measured Concentration Value (AUC[0-tlast]) of Ixekizumab

Area under the plasma concentration versus time curve from time zero to the last measured concentration value (AUC\[0-tlast\]). AUC 0-tlast is equal to AUC (0-85) days where the last time point was 85 Days ± 3 Days.

Time frame:
Predose, Day 3, Day 5, Day 11, Day 15, Day 22, Day 29, Day 36, Day 43, Day 57, Day 71 and Day 85 Post Dose
Reported as:
Geometric mean · microgram*day/milliliter (ug*day/mL)
PK: Area Under the Plasma Concentration Versus Time Curve (AUC) From Time Zero to the Last Measured Concentration Value (AUC[0-tlast]) of Ixekizumab
microgram*day/milliliter (ug*day/mL)Ixekizumab (Reference)Ixekizumab (Test 1)Ixekizumab (Test 2)
PK: Area Under the Plasma Concentration Versus Time Curve (AUC) From Time Zero to the Last Measured Concentration Value (AUC[0-tlast]) of Ixekizumab146 ± 43153 ± 37163 ± 33
PrimaryPK: Area Under the Plasma Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of Ixekizumab.

Area under the plasma concentration versus time curve from zero to infinity (AUC\[0-∞\]) of a single dose of Ixekizumab.

Time frame:
Predose, Day 3, Day 5, Day 11, Day 15, Day 22, Day 29, Day 36, Day 43, Day 57, Day 71 and Day 85 Post Dose
Reported as:
Geometric mean · ug*day/mL
PK: Area Under the Plasma Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of Ixekizumab.
ug*day/mLIxekizumab (Reference)Ixekizumab (Test 1)Ixekizumab (Test 2)
PK: Area Under the Plasma Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of Ixekizumab.152 ± 45159 ± 38170 ± 34

Adverse events

Collected over Up to 12 Weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ixekizumab (Reference)0/33 (0%)0/33 (0%)4/33 (12.1%)
Ixekizumab (Test 1)0/33 (0%)0/33 (0%)2/33 (6.1%)
Ixekizumab (Test 2)1/33 (3%)1/33 (3%)5/33 (15.2%)
Most frequent serious events
Most frequent serious events
EventIxekizumab (Reference)Ixekizumab (Test 1)Ixekizumab (Test 2)
Periorbital abscessInfections and infestations0/330/331/33
Phaeohyphomycotic brain abscessInfections and infestations0/330/331/33
SinusitisInfections and infestations0/330/331/33
Cerebral venous thrombosisNervous system disorders0/330/331/33
Most frequent other events
Most frequent other events
EventIxekizumab (Reference)Ixekizumab (Test 1)Ixekizumab (Test 2)
Upper respiratory tract infectionInfections and infestations0/330/333/33
Injection site reactionGeneral disorders1/332/331/33
CoughRespiratory, thoracic and mediastinal disorders2/330/330/33
RhinorrhoeaRespiratory, thoracic and mediastinal disorders1/330/332/33

Baseline characteristics

All randomized participants who received at least one dose of study drug.

Age, Continuous
Age, Continuous(years)Ixekizumab (Reference)Ixekizumab (Test 1)Ixekizumab (Test 2)Total
Mean42.5 ± 13.541.9 ± 15.949.2 ± 15.244.5 ± 15.1
Sex: Female, Male
Sex: Female, Male(Participants)Ixekizumab (Reference)Ixekizumab (Test 1)Ixekizumab (Test 2)Total
Female22232469
Male1110930
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Ixekizumab (Reference)Ixekizumab (Test 1)Ixekizumab (Test 2)Total
Hispanic or Latino14111136
Not Hispanic or Latino19222263
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Ixekizumab (Reference)Ixekizumab (Test 1)Ixekizumab (Test 2)Total
American Indian or Alaska Native0000
Asian1001
Native Hawaiian or Other Pacific Islander0000
Black or African American77620
White25252777
More than one race0101
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(Participants)Ixekizumab (Reference)Ixekizumab (Test 1)Ixekizumab (Test 2)Total
United States33333399
08

Study locations

1 site
  • Covance Clinical Research Inc
    Daytona Beach, Florida 32117, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2019 to primary completion in Jun 2019, 4 months.

Results were first posted in Jun 2020, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 19, 2019
First posted
Feb 20, 2019
StartActual
Jan 29, 2019
Primary completionActual
Jun 7, 2019
CompletionActual
Jun 7, 2019
Results first posted
Jun 24, 2020
Last update
Jun 24, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 24, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03848416
Responsible party
Sponsor
First posted
Feb 20, 2019
Start date
Jan 29, 2019
Primary completion
Jun 7, 2019
Completion
Jun 7, 2019
Results posted
Jun 24, 2020
Last update
Jun 24, 2020

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ixekizumab

Start the discussion